carfilzomib

P=N/A, N=50, Recruiting, The First Affiliated Hospital of Soochow University

P3, N=650, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2025 --> Feb 2026

Although the efficacy of carfilzomib was difficult to confirm due to its toxicity in our models, ibrutinib showed comparable efficacy to a standard combination of chemotherapy drugs. Together, our data provide a new culture method for IVLBCL PDX cells and a rationale for translating ibrutinib to clinical use in IVLBCL patients.

P1/2, N=70, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Oct 2024 --> Nov 2032 | Trial primary completion date: Oct 2024 --> Apr 2029

P1/2, N=37, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P1/2, N=63, Completed, European Myeloma Network B.V. | Active, not recruiting --> Completed

P2, N=50, Active, not recruiting, University of Arkansas | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=586, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=1200 --> 586

P2, N=28, Not yet recruiting, Roswell Park Cancer Institute

P1, N=15, Not yet recruiting, Roswell Park Cancer Institute

Iber-Dd and Iber-DKd are safe combinations and able to eliminate MRD persistent after modern induction therapy and ASCT in NDMM. This study is ongoing, complete safety and efficacy results from part 1 and updated results from part 2 will be presented at the meeting.

P3, N=440, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

P=N/A, N=160, Recruiting, Takeda | N=320 --> 160 | Trial completion date: Oct 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jun 2027

P2, N=74, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Mar 2025 --> Mar 2026

P2, N=52, Active, not recruiting, Academic and Community Cancer Research United | Recruiting --> Active, not recruiting

P4, N=70, Recruiting, Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University

PIs enhance the anti-leukemic efficacy of CAR-expressing allogeneic NK cells against AML in vitro and in vivo, warranting further exploration of this combinatorial treatment within early phase clinical trials.

P1/2, N=300, Recruiting, Karyopharm Therapeutics Inc | Active, not recruiting --> Recruiting

Patients were treated either with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant (KRd-ASCT, NCT01816971) or with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd, NCT03500445). In addition to the prognostic significance of MS(-) at any level, the depth of MS negativity is associated with longer PFS. LC-MS(-) and/or 10-6 MRD(-) patients experience long term disease control. The potential of LC-MS to enhance the prognostic potential of MRD at 10-6 for predicting longer disease control is currently under evaluation in a larger sample set.

No abstract available

P1, N=189, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.

P=N/A, N=36, Completed, Central Hospital, Nancy, France

P3, N=450, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting

P1/2, N=66, Recruiting, Hackensack Meridian Health | Suspended --> Recruiting

P1, N=10, Recruiting, Tel-Aviv Sourasky Medical Center | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: Apr 2024 --> Apr 2026

P3, N=318, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P1, N=90, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Dec 2025

P3, N=250, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting

P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

P2, N=18, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting

Our findings suggest the possibility of a better response to anti-CDKN2A therapy with Villosol in KRAS-mutant CRC. Also, the more marked up-regulation of genes in the proteasome pathway in CRC tissue, especially with the KRAS mutation and MSI, may suggest a potential role of a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) in selected CRC patients if necessary.

P2, N=64, Not yet recruiting, Sanofi | Initiation date: Jun 2024 --> Nov 2024

P1/2, N=23, Terminated, Jennifer Amengual | Completed --> Terminated; Lack of funding

P1/2, N=42, Recruiting, The Methodist Hospital Research Institute

P1, N=35, Terminated, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jul 2024; Inadequate accrual rate

These findings suggest that specific miRNAs could serve as predictive biomarkers for CVAE and provide insights into the underlying mechanisms of CFZ-CVAE. Further investigation is warranted before these findings can be applied in clinical settings.

P2, N=75, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting

P=N/A, N=50, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting

P1/2, N=101, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2

P1, N=18, Recruiting, Hackensack Meridian Health | Suspended --> Recruiting

P1, N=15, Completed, Takeda | Active, not recruiting --> Completed | N=120 --> 15

P1/2, N=70, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting